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Summary of Progress  
We have been focused on improving the quality of our crystals of signal peptide peptidase (SPP), 
which is a prerequisite for structure determination, and a major rate-limiting step of our project.  
Our ability to obtain initial crystals strongly indicates that this project ultimately will be 
successful. We are taking a multi-pronged approach to improve the crystals, including testing for 
stability and crystallization in different detergents, improving purification protocols, exploring 
2D cryo-electron diffraction, and crystallization in complex with a chaperone.  Our progress is 
summarized in further detail below. 
 
Review of Specific Aims/Objectives 
Aim #1:  Express and purify SPP orthologs.  
 
This aim was well underway last year, and we are now able to express and purify all variants of 
SPP for our studies, including catalytically impaired mutants.  Variants include H. marismortui 
(mSPP), A. fulgidus (A. ful SPP), H. salinarum (H. sal SPP), T. acidophilum and T. volcanium 
SPPs and their respective double catalytic mutants (DM), discussed below, among others. Thus, 
our focus is now on achieving Aims 2 and 3, described in more detail below. 
 
Aim #2: Crystallize SPP.  
 
Crystallization of wild-type mSPP.  Last year we reported crystallization of mSPP with 
diffraction limits of ~ 6 Å resolution. This continues to be the diffraction limit of our three-
dimensional crystals (see Aim 3).  To 
expand our crystallographic horizons, 
we have been working in 
collaboration with Prof. Ingeborg 
Schmidt Krey, an electron 
crystallographer at Georgia Tech who 
specializes in solving 2D membrane 
protein structures.  Indeed, initial 
results look promising. Dialysis to 
remove detergent and reconstitute in 
liposomes (Lipid to Protein Ratio 15, 
T = 24°C) results in two-dimensional 
crystals with ordered mSPP as judged 
by Fourier transform analysis of the 
electron diffraction pattern (Figure 1). 
Optimization is underway. 
 
Figure 1. 2D crystallization of mSPP. mSPP 
reconstituted in proteoliposomes  produces 
membranes (left). Fourier transform analysis of a 
small region of the membranes (right) demonstrates 
a lattice. 
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New complexes for membrane protein crystallization.  
In parallel to efforts to extend the diffraction 
limit of wild-type mSPP crystals, we are investigating 
new chaperones for complexation with mSPP. My lab 
has teamed up with Jennifer Maynard at UT Austin, a 
protein engineer, to generate tailored antibody fragments 
with high affinity for epitopes on SPP. The first 
antibody fragment generated has rather high affinity for 
an EE-tag installed in SPP and was readily crystallized 
(Figure 2). We are now pursuing the cocrystallization of 
mSPP and this new chaperone, as well as developing 
this method more broadly, including different types of 
antibody fragments and different epitopes for 
recognition. 
 
Aim #3: Solve the crystal structure of SPP by itself 
and with inhibitors.   
 
Our best apo SPP crystals to date (~5x5x20 µm) still diffract to ~6 Å resolution, with several 
reflections observed at ~4 Å resolution, as reported in the original application.  We have not yet 
improved the resolution of the crystals. 
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Overall impressions/comments 
I am incredibly appreciative for the AFAR funds. Since the start of the AFAR grant, I hired a 
new postdoctoral fellow, Dr. Jason Drury, and attracted several graduate and undergraduate 
students to the “SPP subgroup.” These funds have been indispensible in giving my lab more 
freedom in pursuing new avenues for the structure of an intramembrane aspartyl protease.  For 
example, the tailored antibody fragment work was awarded an NIH R21 (PI: Lieberman), and 




Figure 2. Crystal lattice of 
antibody fragment 3D5/EE_48. 
(a) Asymmetric unit. (b) Lattice 
structure with size of central cavity 
indicated. Lighter hue indicates the 
light variable chain while the 
darker hue indicates heavy variable 
chain. Complementary determining 
regions are depicted in red. 
